Tosoh Bioscience Joins enGenes-led Consortium to Advance Continuous E. coli Manufacturing

Tosoh Bioscience is proud to announce its participation in a consortium led by enGenes Biotech GmbH (enGenes)

Griesheim, Germany/King of Prussia, PA - Tosoh Bioscience is proud to announce its participation in a consortium led by enGenes Biotech GmbH (enGenes), a recombinant proteins specialist CDMO, which has received major funding from the Austrian Research Funding Agency (FFG) to advance continuous manufacturing based on Escherichia coli (E. coli). The FFG has committed to providing total funding of 2.7 Million EUR for the ECOnti project, with an estimated total investment of 3.6 Million EUR.

The ECOnti project, titled "Accelerated, low ecological footprint, manufacturing platform for continuous production of biotechnological products," aims to develop a fully integrated and automated continuous upstream and downstream process at up to 10 L batch size. This small-scale development platform will enable the industry to develop continuous bioprocesses, implement model predictive control, and perform economic modeling to demonstrate potential cost savings of continuous manufacturing compared to batch-based manufacturing.

Tosoh Bioscience will contribute its expertise in continuous downstream processing (DSP) and its innovative Octave™ BIO technology to the six-member consortium. Other members include enGenes, the University of Natural Resources and Life Sciences (BOKU), Qubicon AG, Novasign, and SimVantage.

Sebastian Thürmann, Product Manager MCC at Tosoh Bioscience, commented, "We are thrilled to be part of this pioneering project to establish a fully integrated continuous bioprocess for E. coli. Our collaboration in this project is part of our constant effort to proactively tackle the current challenges of biomanufacturing and will help drive innovation in the biopharma industry."

The initiative aims to overcome current barriers in continuous manufacturing using E. coli and other bacteria and develop a small-scale process that establishes model predictive control to dominate a fully integrated process at full scale.

Mark Pagkaliwangan, Global Product Manager MCC at Tosoh Bioscience, added, "This project demonstrates Tosoh Bioscience's commitment to providing cutting-edge solutions in bioprocessing. Our collaboration with other industry leaders within the ECOnti consortium will undoubtedly help overcome current barriers in continuous manufacturing and bring us closer to achieving sustainable and cost-effective production of biomolecules."

The technology developed within the ECOnti project is expected to offer several key advantages, including smaller production facilities, reduced water consumption, lower energy consumption and CO2 emissions, end-to-end process control, full digitization and automation, higher product yields, and enhanced process stability.


Tosoh Bioscience LLC/GmbH supplies liquid chromatography products to laboratories and manufacturing plants across the Americas and EMEA. Our diverse customer base includes biotechnology and pharmaceutical companies and various other industries that rely on our U/HPLC columns and systems for sample analysis. The revolutionary LenS™3 Multi-Angle Light Scattering Detector offers advanced measurement capabilities for molecular weight (MW) and radius of gyration (Rg) of synthetic polymers, polysaccharides, proteins, and biopolymers. The EcoSEC Elite™ GPC System, a dedicated all-in-one GPC solution, is predominantly used in the chemical and polymer industries, while the EcoSEC™ High-Temperature GPC System caters to the polyolefin and oil sectors.

In the biotechnology field, our preparative chromatography resins TOYOPEARL® and TSKgel® are crucial for purifying proteins and nucleic acids for medical applications. Our SkillPak™ columns, pre-packed with these resins, enable rapid and efficient purification method development. The recent introduction of Octave Multi-Column Chromatography (MCC) systems completes our bioprocessing portfolio, providing a holistic solution for MCC purification of antibodies and other biomolecules for the biopharma industry.

As a subsidiary of Japan's Tosoh Corporation, we are part of the global Tosoh Group, which comprises over 100 companies and a diverse workforce of more than 13,600 people. The group generated net sales of ¥918.6 billion (US$8.2 billion at an average exchange rate of ¥112.4 to the US dollar) in fiscal 2022, which ended March 31, 2022. Tosoh's Bioscience Division offers products and solutions for separation and purification, as well as clinical diagnostics, serving customers worldwide.

Tosoh Bioscience, EcoSEC, EcoSEC Elite, TOYOPEARL, and TSKgel are registered trademarks of Tosoh Corporation.
LenS and SkillPak are trademarks of Tosoh Bioscience LLC.


Marketing Communications
Tosoh Bioscience LLC

[email protected]